RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm

Core Viewpoint - REGENXBIO Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its gene therapy product RGX-111, which has led to significant stock price declines following adverse developments in clinical trials [2][3]. Group 1: Allegations and Impact - The lawsuit claims that REGENXBIO provided investors with overly positive information about RGX-111's potential success based on favorable biomarker and safety data from ongoing trials while concealing material adverse facts about the therapy's efficacy and safety [2]. - Following the announcement of a clinical hold by the FDA due to the discovery of a CNS tumor in a trial participant, REGENXBIO's stock price dropped from $13.41 to $11.01, marking a decline of 17.8% in one day [2]. Group 2: Class Action Details - Shareholders who purchased RGNX shares between February 9, 2022, and January 27, 2026, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for April 14, 2026 [3]. - Participants in the class action will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to join [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders, emphasizing its commitment to protecting investors' rights against deceit and fraud [4].